Basking In Phase III Telaprevir Success, Vertex Maps Hepatitis C Market
Executive Summary
After releasing glowing topline Phase III results for telaprevir, Vertex took pains to reassure investors that it is up to the commercial job of competing against Big Pharma and that it has done its homework on the developing hepatitis C market
You may also be interested in...
Vertex Advances Toward Telaprevir Approval
The first Phase III results for the hepatitis C direct-acting antiviral give the firm reason to be confident.
Merck R&D: A Jam-Packed Pipeline But Much Of It Wait-And-See
Following the acquisition of Schering-Plough, Merck has one of the most robust pipelines in the industry, but after an R&D day May 11, much of the most interesting data is still yet to be seen.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011